Melbourne: Drugs already developed to treat bacterial infection can be re-purposed to cure the mosquito-borne viral disease dengue, Australian researchers have found.
The scientists from University of Queensland identified similarities in how the body reacted to dengue virus and bacterial infections.
As drugs for bacterial infections are already available, the researchers believe that clinical trials for a dengue fever treatment could start within a year.
"We have discovered that the dengue virus NS1 protein acts as a toxin in the body, in a similar manner to the way bacterial cell wall products lead to septic shock in bacterial infections," said Paul Young, professor at University of Queensland.
"For the past 20 to 30 years, researchers and pharmaceutical companies have been developing drug candidates to inhibit the body's damaging responses to these bacterial infections. So drugs are already available that have gone through phase three clinical trials," Mr Young said.
Dengue virus is estimated to infect up to 400 million people globally each year. The World Health Organisation ranks it as the most important mosquito-borne viral disease in the world.
Professor Young said mosquito-borne dengue virus was an increasing problem in tropical and sub-tropical areas, with more than 2.5 billion people in more than 100 countries at risk of infection.
Dengue typically causes a debilitating fever but can progress to potentially fatal dengue hemorrhagic fever and dengue shock syndrome.
"Despite this significant global health burden, no vaccine or drug has yet been licensed," Mr Young pointed out.
"I hope our discoveries in the lab will translate to the patient bedside and eventually help those who suffer from dengue infection around the world," said doctoral student Naphak Modhiran, who came from Thailand to work on the project.
The findings were detailed in the journal Science Translational Medicine.
The scientists from University of Queensland identified similarities in how the body reacted to dengue virus and bacterial infections.
As drugs for bacterial infections are already available, the researchers believe that clinical trials for a dengue fever treatment could start within a year.
"For the past 20 to 30 years, researchers and pharmaceutical companies have been developing drug candidates to inhibit the body's damaging responses to these bacterial infections. So drugs are already available that have gone through phase three clinical trials," Mr Young said.
Advertisement
Professor Young said mosquito-borne dengue virus was an increasing problem in tropical and sub-tropical areas, with more than 2.5 billion people in more than 100 countries at risk of infection.
Advertisement
"Despite this significant global health burden, no vaccine or drug has yet been licensed," Mr Young pointed out.
Advertisement
The findings were detailed in the journal Science Translational Medicine.
COMMENTS
Advertisement
Dengue Can Seriously Affect The Brain, Nervous System, Say Doctors 13-Year-Old Boy Dies Due To Dengue In Karnataka Amid Spike In Cases Reduce Your Risk Of Dengue This Monsoon By Following These Precautionary Tips What Trump Rally Shooter Did On Last Day Of His Life Under-Fire Trainee IAS Officer Accuses Pune Collector Of Harassment Trainee IAS Officer Puja Khedkar Recalled To Academy, Training Put On Hold Four In Five Americans Fear Country Is Sliding Into Chaos: Polls Royal Enfield Guerrilla 450 Launched In India; Prices Start At Rs. 2.39 Lakh Admission Deadline Extended For EWS And Special Needs Children Track Latest News Live on NDTV.com and get news updates from India and around the world.